Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details)

v2.4.0.6
Subsequent Events (Details) (USD $)
 12 Months Ended 1 Months Ended 2 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Mar. 31, 2013
Subsequent Event [Member]
Mar. 31, 2013
Subsequent Event [Member]
Series X Warrants [Member]
Mar. 31, 2013
Subsequent Event [Member]
Montaur Credit Facility [Member]
Mar. 31, 2013
Subsequent Event [Member]
Restricted Stock [Member]
Feb. 28, 2013
Subsequent Event [Member]
Ladenburg Thalman and Company Inc. [Member]
FDA Approval of Lymphoseek                
Number of restricted stock units vested during period             510,000  
Aggregate fair value of vested restricted stock             $ 1,600,000  
Increase in borrowing capacity           20,000,000    
Public Offering of Common Stock                
Stock issued during period, shares               1,542,389
Common stock issued, price per share               $ 3.1
Proceeds from issuance of common stock, net 2,724,189 7,198,373 7,092,163         4,400,000
Warrant Exercise [Abstract]                
Warrants exercised         3,000,000      
Number of shares issued from exercise of warrants       3,000,000        
Proceeds from exercise of warrants       $ 1,380,000